1. Home
  2. GVH vs ONCO Comparison

GVH vs ONCO Comparison

Compare GVH & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Globavend Holdings Limited

GVH

Globavend Holdings Limited

N/A

Current Price

$1.05

Market Cap

2.6M

Sector

N/A

ML Signal

N/A

Logo Onconetix Inc.

ONCO

Onconetix Inc.

N/A

Current Price

$0.62

Market Cap

3.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GVH
ONCO
Founded
2016
2018
Country
Australia
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.6M
3.0M
IPO Year
2023
2021

Fundamental Metrics

Financial Performance
Metric
GVH
ONCO
Price
$1.05
$0.62
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
345.3K
★ 6.7M
Earning Date
07-14-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 22.80
EPS
★ N/A
N/A
Revenue
N/A
★ $815,371.00
Revenue This Year
$1.85
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$0.74
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.87
$0.09
52 Week High
$6.46
$6.73

Technical Indicators

Market Signals
Indicator
GVH
ONCO
Relative Strength Index (RSI) 43.31 41.89
Support Level $0.87 $0.09
Resistance Level $1.13 $1.09
Average True Range (ATR) 0.07 0.17
MACD 0.01 -0.02
Stochastic Oscillator 16.43 5.02

Price Performance

Historical Comparison
GVH
ONCO

About GVH Globavend Holdings Limited

Globavend Holdings Ltd is an e-commerce logistics provider, it provides integrated cross-border logistics services from Hong Kong to Australia and New Zealand, where it provides customers with a one-stop solution from parcel consolidation to air freight forwarding, customs clearance, on-carriage parcel transportation and delivery. It operates in logistics and freight forwarding industry, which involves the provision of services such as freight transport, freight forwarding, warehouse management, and distribution.

About ONCO Onconetix Inc.

Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. The company owns Proclarix, an in vitro diagnostic test for prostate cancer, approved for sale in the European Union. Additionally, it is focused on marketing Proclarix in the U.S. as a lab-developed product. Onconetix operates in one segment: commercial. Geographically, the company generates maximum revenue from Switzerland and the rest from the United Kingdom.

Share on Social Networks: